CD276 and neoplasm: Third, most SGD-1882/talirine PBD-based ADCs that failed to advance through clinical trials, such as SGN-CD33A, SGN-CD70A, SGN-CD19B, SGN-CD123A, and SGN-CD352A, were targeted against hematological tumors, even though hydrophobic PBDs can readily diffuse out of target cells upon uptake and release in lysosomes.61,62 Finally, unlike previous SGD-1882-linked ADCs that recognized only the human target antigen in xenograft tumor studies, m276-SL-PBD cross-reacted with both human and mouse CD276 and exhibited less toxicity and increased potency and efficacy against much larger tumors.